I have held CRX for too long, but initially bought on seeing the theoretical advantages of the "systems" for evaluation of drugs at potentially less costs than other systems.

I bought the shares initially long out and bought a number of times at lower and lower prices.

From the fundamentals it appears to be beginning to show profits, and projections are also good.

The charts point to a break out reversal which is being sustained.
On a 12-18ths time scale should do well. I wouldn't trade it, as the spread for me is too wide.

BDYOH

Expansion of Bioanalytical Capabilities

Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the expansion of their bioanalytical capabilities within the BioHub site at Alderley Park in the UK to increase its offering to both existing customers and new customers in new markets.

The new instruments include a Waters Xevo® G2-S QTof high resolution accurate mass spectrometer ("QTof"), a LabLogic Beta-Ram® radiochemical detector and a Waters Atmospheric Pressure Gas Chromatography (APGC) system. This investment enables Cyprotex to improve its services to its existing pharmaceutical customers as well as unlock future potential in new markets such as the chemical and personal care markets.

Assessing the metabolites formed following drug exposure is a key part of the drug development process. The Waters Xevo® G2-S QTof mass spectrometer is one of the most advanced instruments for this purpose. By determining the accurate mass of the metabolites it enables more precise structural characterisation to be achieved. The new QTof can also be linked to a LabLogic Beta-Ram® radiochemical detector which complements this service allowing detection of radiochemicals and quantification of radiolabelled metabolites formed.

Although our current analytical equipment is suitable for the majority of molecules we test, it is not appropriate for certain classes of compounds and chemicals. As Cyprotex expands into the personal care and chemicals market, an ability to analyse more volatile compounds is required. The Company has therefore invested in gas chromatography which is a more appropriate platform for these types of molecules. Another key trend in the market is the preclinical development of large molecules. The QTof can analyse an extended range of molecular weights meaning the analysis of larger molecules is more achievable.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the expansion of the bioanalytical facility:

"Characterising the structural identity of drug metabolites is a critical part of the drug development process. By investing in the QTof and the radiochemical detector we can now provide a comprehensive service which is appropriate for late stage preclinical development projects required by the regulatory authorities.

"As we expand into new markets we are observing a shift in the requirements for bioanalysis, and we are adapting our business accordingly. We now have a wide range of solutions to cover our differing customers' needs, allowing us to grow our existing business as well as attract customers from new markets."

Proposed Share Consolidation and Notice of General Meeting

Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announces that it has today posted a circular to shareholders dated 3 July 2014 ("Circular") setting out details of a proposed consolidation of share capital (" Share Consolidation").

Under the Share Consolidation it is proposed that every 10 existing ordinary shares will be consolidated into one new ordinary share, with any fractional entitlements arising from the Share Consolidation being aggregated and sold in the market on behalf of the relevant Shareholders and the proceeds donated to charity.

The Board believes that the consolidation of share capital will result in a more appropriate number of shares in issue for a company of Cyprotex's size in the UK market. The Share Consolidation may also help to make the Shares more attractive to investors and may result in a narrowing of the bid/offer spread, thereby improving liquidity.

The Share Consolidation is subject to the approval of shareholders at a general Meeting which is being held at 11.00 a.m. on 24 July 2014. If the resolution is approved, trading in the consolidated shares should begin on 28 July 2014.

Following the Share Consolidation, Shareholders will still hold the same proportion of the Company's ordinary share capital as before the Share Consolidation (save in respect of fractional entitlements). Other than a change in nominal value, the New Ordinary Shares will carry equivalent rights under the Articles of Association to the Existing Ordinary Shares.

Further details of the Share Consolidation are set out in the Circular which will be made available on the Company's website at www.cyprotex.com.

The Definitions which apply in the Circular have been used in this announcement.

Has this consolidation gone thro' at 10-1?


Lost in France!

oui - 28 July 2014.

DC.

Mercy!


I thought so, but wished differently.


Hoping I could die a rich man.


Interesting company, which will probably be bought out at sometime or other.

Good luck Fred. :-))

A bit of life here since the New year?

I am still holding on to these and surprised to be in profit.

But still wonder if it will be bought out.

I thought it was a long distance runner when I bought.

But it seems a b, long track.

I've have a few and I'm nearly back to break even - I must try and remember why I bought them!

I know the feeling!

It was one of the last aim or small caps I bought!

One learns.

But why was I so bloody slow!

-----=--

Final Results

Cyprotex PLC (AIM: CRX), the preclinical ADME-Tox services company, today reports its final results for the year ended 31 December 2014.

Financial Highlights

· Strong revenue growth up 18.4% to £11.57 million (2013: £9.77 million)

· CeeTox acquisition contributed £1.12 million of total revenue

· Excluding CeeTox revenue grew 7.0% (2013: 17.3%)

· Gross margins decreased to 75.0% (2013: 80.0%) predominantly as a result of greater outsourcing in the period

· Operating loss of £0.71 million, excluding goodwill impairment, (2013: Operating profit of £0.61 million)

· Goodwill impairment relating to US Operations of £3.04 million (2013: £nil)

· Underlying EBITDA^ of £0.61 million (2013: £1.54 million)

· Loss per share at 18.59 pence (2013: loss per share 3.56 pence^^)

· Cash of £2.9 million as at 31 December 2014 (2013: £7.1 million)



^ excluding share-based payment charge and impairment of intangibles
^^ rebased following a ten for one share consolidation


Operational Highlights

· Acquisition and integration of CeeTox business completed

· Expanded into the BioHub at the former Astra Zeneca Alderley Park site, and transferred a number of assays and staff to accommodate further growth in revenues

· Significant investment in several major new products and services. These include a new High Throughput Facility in Watertown, a new suite of drug transporter assays, a new high resolution QTof mass spectrometer for improved metabolite identification services and new toxicology analysis equipment in Macclesfield

· Dependence on one large customer and one large Government agency has been reduced at Kalamazoo

· 171 new customers in 2014 (2013: 136 customers)

· 407 total customers served in 2014 (2013: 325 customers)

· Largest customer contributed 8.1% of revenues (2013: 9.8%)

· Commenced and completed two large contracts for the US Environmental Protection Agency (EPA)

more....

Trading Update

Trading update

The financial performance of the Company for the first 5 months of the year is ahead of expectations driven by strong growth in UK revenues and whilst there remain challenges, particularly in the US operations, the Board expects that its full year revenues and profits will exceed current market expectations.

Interim Results 2015 Revenues up significantly and return to operational profitability

Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today reports its interim results for the half year to 30 June 2015.


Financial Highlights

· Revenues up 28% to £6.93 million (H1 2014: £5.41 million).
· Gross margins were 76.7% (H1 2014: 78.7%, FY 2014: 75.0%).
· Operating profit of £0.36 million (H1 2014: Operating loss £0.58 million).
· Underlying EBITDA^ of £1.10 million (H1 2014: £0.04 million).
· Cash of £4.13 million (H1 2014: £4.56 million, FY 2014: £2.93 million).

^ excluding share based payment charge

Operational Highlights

· The investment plan for all 4 sites which commenced in early 2014 and completed in early 2015 is now bearing fruit and has contributed significantly to the revenue growth seen in H1.
· Investment in a new drug transporter facility for the support of full drug-drug interaction studies for regulatory submission, QTof based metabolite identification and 3D tissue-based toxicology assays at our UK sites has been highly successful in revenue generation. Successful translocation of our existing toxicology facility to a second UK site at the BioHub, Alderley Park.
· Validation of a replica High Throughput (HT) ADME screening platform at our Watertown site has also been completed and the platform is now supporting large scale screening contracts for the US Government.
· Investment in upgrading our toxicology assays at our Kalamazoo site (formerly CeeTox) to bring them fully into OECD compliance has been completed and these assays, along with our proprietary SenCeeTox® skin sensitization assays have been well received by existing and new customers.
· Website upgrades including a new blog page have contributed to a noticeable improvement in the global recognition of the Cyprotex brand.
· 103 new customers in H1 2015 (111 in H1 2014).
· Successful completion and continued expansion of two large US Environmental Protection Agency (EPA) contracts.
· Largest customer is 12.3% (FY 2014: 7.8%) of revenues and represents a continuing large strategic deal with a major pharmaceutical company.

Post Period-End Highlights

· Expansion of Research & Development into regulatory genotoxicity services and the creation of a new Biosciences Division across all four global sites.

Trading Update

Trading update

The financial performance of the Company for the first nine months of the year is ahead of expectations driven by continuing strong growth in UK revenues and whilst there still remain challenges as referred to in previous announcements, particularly in the US operations which still need some attention but which are much improved from earlier in the year, the Board expects that its full year revenues and EBITDA will exceed current market expectations.

That will be a quid!

That will be £1.16!

130p touched earlier.

Final Results

Financial Highlights

· Strong revenue growth up 34.9% to £15.61 million (2014: £11.57 million)

· Gross margins increased to 77.3% (2014: 75.0%)

· Operating profit of £1.98 million, (2014: Operating loss, excluding goodwill impairment, of £0.71 million)

· Underlying EBITDA^ of £3.40 million (2014: £0.61 million)

· Cash generated from operations of £3.48 million (2014: used in operations £1.32 million)

· Exceptional non-cash finance charge in respect of Embedded Derivative associated with Loan Notes of £8.07 million (2014: finance income £0.24 million) yielding a basic loss per share at 28.99 pence (2014: loss per share 18.59 pence)

· Underlying basic earnings^^ per share of 6.94 pence (2014: loss 19.67 pence)

· Cash of £5.4 million as at 31 December 2015 (2014: £2.9 million)

^ excluding share-based payment charge and impairment of intangibles
^^ excluding movement in Embedded Derivative valuation associated with Redeemable and Convertible Loan Notes

Operational Highlights

· New Bioscience division for phenotypic and target based drug discovery service

· Partnership in the EC-funded EU-ToxRisk Consortium with an estimated value of €1 million over 6 year period

· Expansion of 3D cellular model capabilities with introduction of beating cardiac microtissue

· Launched new software solutions, chemPKTM and chemTox as virtual screening approaches for predicting pharmacokinetics and toxicity

· New blog launched on Cyprotex website and increased social media presence

· 243 new customers in 2015 (2014: 171 customers)

· 488 total customers served in 2015 (2014: 407 customers)

· Largest customer contributed 9.6% of revenues in 2015 (2014: 8.1%)

Trading Update

Cyprotex PLC, the preclinical ADME-Tox services company, provides an update on revenue and profit guidance for the first quarter of 2016.

The financial performance of the Company for the first quarter of the year is significantly ahead of the Boards' expectations, comparative period performance and internal budgets.

The Board also confirms that the Company's strategic review is progressing.

Trading Update and Notice of Interim Results


Cyprotex PLC, the preclinical ADME-Tox services company, provides an update on revenue and profit guidance for the first half of 2016.

The financial performance of the Company for the first half of the year is significantly ahead of the Boards expectations, comparative period performance and internal budgets.

The Board expects to announce the Interim Results of the Company on 2 August 2016.

The Board also confirms that the Company's strategic review is progressing.

This announcement contains inside information.